chloroquine has been researched along with Complications, Infectious Pregnancy in 92 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the safety of chloroquine (CQ) as prophylaxis against Plasmodium vivax infection during pregnancy." | 9.12 | Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. ( Arunjerdja, R; Greenwood, B; Htway, M; McGready, R; Nosten, F; Paw, MK; Pimanpanarak, M; Viladpai-Nguen, SJ; Villegas, L; White, NJ, 2007) |
| "To determine the effect of chloroquine chemoprophylaxis during pregnancy on birth weights, a randomized trial was carried out in 1987 and 1988 in Banfora, Burkina Faso (West Africa)." | 9.07 | Effect of chloroquine chemoprophylaxis during pregnancy on birth weight: results of a randomized trial. ( Barro, D; Breart, G; Carnevale, P; Cot, M; Roisin, A; Verhave, JP; Yada, A, 1992) |
| " A major determinant of compliance with treatment in this environment is the pruritus chloroquine induces when ingested." | 7.72 | Pattern of chloroquine-induced pruritus in antenatal patients at the University College Hospital, Ibadan. ( Adeniji, AR; Aimakhu, CO; Fehintola, FA; Olayemi, O; Osungbade, A; Udoh, ES, 2003) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 7.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Six hundred and twenty pregnant women, living under conditions of year-round transmission of malaria in a rural coastal area of Madang, Papua New Guinea (PNG), were followed while attending mobile antenatal clinics and receiving chloroquine prophylaxis (300 mg base weekly)." | 7.68 | Failure of chloroquine prophylaxis for falciparum malaria in pregnant women in Madang, Papua New Guinea. ( Alpers, M; Brabin, BJ; Brabin, L; Eggelte, T; Ginny, M; Van der Kaay, HJ, 1990) |
| "A cohort of 169 births to women who were exposed throughout pregnancy to chloroquine 300 mg base once a week for chemosuppression of malaria was studied." | 7.67 | Safety of chloroquine in chemosuppression of malaria during pregnancy. ( Cordero, JF; Wolfe, MS, 1985) |
| " A dosage of chloroquine base (25 mg/kg of body weight) was given to women over a 3-day period, followed by 5 mg/kg doses administered weekly for 4 weeks." | 5.28 | Malaria and pregnancy in Cameroonian women. Effect of pregnancy on Plasmodium falciparum parasitemia and the response to chloroquine. ( Campbell, CC; James, MA; Mvondo, JL, 1992) |
| "The weekly chemoprophylaxis of malaria during pregnancy with chloroquine (CQ) has become problematic with the increasing resistance of Plasmodium falciparum to this drug." | 5.14 | Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens. ( Bougouma, EC; Diarra, A; Konaté, AT; Nébié, I; Ouedraogo, A; Sirima, SB; Tiono, AB, 2009) |
| "Intermittent preventive treatment with three doses of sulfadoxine-pyrimethamine is a more effective strategy to prevent maternal anemia during pregnancy in Burkina Faso." | 5.13 | [Comparative impact of three malaria preventive regimens during pregnancy on maternal anemia due to malaria in Burkina Faso]. ( Bougouma, EC; Diarra, A; Konaté, AT; Nébié, I; Ouédraogo, A; Sirima, SB; Tiono, AB, 2008) |
| " The purpose was to compare the efficacy of two regimens using chloroquine (CQ) or sulfadoxine-pyrimethamine (SP) during pregnancy and delivery in a village located in an endemic area of Mali." | 5.12 | [Randomized clinical trial of two malaria prophylaxis regimens for pregnant women in Faladie, Mali]. ( Dabo, CA; Diallo, M; Diarra, MA; Doumbo, O; Kayentao, K; Ongoiba, A; Sangho, H; Saye, R; Yattara, O, 2007) |
| "To assess the safety of chloroquine (CQ) as prophylaxis against Plasmodium vivax infection during pregnancy." | 5.12 | Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. ( Arunjerdja, R; Greenwood, B; Htway, M; McGready, R; Nosten, F; Paw, MK; Pimanpanarak, M; Viladpai-Nguen, SJ; Villegas, L; White, NJ, 2007) |
| "To determine the effect of chloroquine chemoprophylaxis during pregnancy on birth weights, a randomized trial was carried out in 1987 and 1988 in Banfora, Burkina Faso (West Africa)." | 5.07 | Effect of chloroquine chemoprophylaxis during pregnancy on birth weight: results of a randomized trial. ( Barro, D; Breart, G; Carnevale, P; Cot, M; Roisin, A; Verhave, JP; Yada, A, 1992) |
| "New studies on the suppressive and curative effects of the anti-malarial drug pyrimethamine in pregnant women from Ilorin, Nigeria showed both ineffective prophylaxis and suppression, and parasite resistance." | 5.06 | Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women. ( Adetoro, O; Akintunde, A; Alakija, T; Breman, JG; Edungbola, LD; Nahlen, BL; Nguyen-Dinh, P; Ogunbode, O, 1989) |
| " Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel." | 4.90 | Malaria. ( Dondorp, AM; Faiz, MA; Hien, TT; Mokuolu, OA; Pukrittayakamee, S; White, NJ, 2014) |
| "Until late 2015, Botswana recommended preventive treatment for pregnant women in malarial regions with chloroquine and proguanil (CP)." | 4.12 | Impact of prophylactic antimalarials in pregnant women living with Human Immunodeficiency Virus on birth outcomes in Botswana. ( Diseko, M; Lockman, S; Mabuta, J; Makhema, J; Mayondi, G; Melton, ML; Mmalane, M; Olaleye, OA; Shapiro, RL; Zash, R, 2022) |
| "The risk of malaria infection is increased during pregnancy, and many countries recommend chloroquine prophylaxis in pregnant women, despite Plasmodium falciparum chloroquine resistance." | 3.73 | High prevalence of Plasmodium falciparum pfcrt K76T mutation in pregnant women taking chloroquine prophylaxis in Senegal. ( Bertin, G; Deloron, P; Fievet, N; Jafari-Guemouri, S; Le Hesran, JY; Ndam, NT; Renart, E; Sow, S, 2005) |
| "Nearly half of all infants in a Ugandan cohort are exposed to chloroquine in the last trimester of pregnancy." | 3.72 | Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. ( Bagenda, D; Kalyesubula, I; Myers, C; Neely, M; Olness, K, 2003) |
| " A major determinant of compliance with treatment in this environment is the pruritus chloroquine induces when ingested." | 3.72 | Pattern of chloroquine-induced pruritus in antenatal patients at the University College Hospital, Ibadan. ( Adeniji, AR; Aimakhu, CO; Fehintola, FA; Olayemi, O; Osungbade, A; Udoh, ES, 2003) |
| "6 months of pregnancy), placed on one of three chloroquine regimens, and followed through delivery." | 3.69 | Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. ( Bloland, PB; Breman, JG; Chilima, B; Chitsulo, L; Mermin, JH; Steketee, RW; Wirima, JJ, 1996) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 3.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Six hundred and twenty pregnant women, living under conditions of year-round transmission of malaria in a rural coastal area of Madang, Papua New Guinea (PNG), were followed while attending mobile antenatal clinics and receiving chloroquine prophylaxis (300 mg base weekly)." | 3.68 | Failure of chloroquine prophylaxis for falciparum malaria in pregnant women in Madang, Papua New Guinea. ( Alpers, M; Brabin, BJ; Brabin, L; Eggelte, T; Ginny, M; Van der Kaay, HJ, 1990) |
| " There was a decrease in spleen rate and a fall in average enlarged spleen size with increasing gestational age for women attending on a first clinic visit and before receiving chloroquine prophylaxis." | 3.67 | A longitudinal study of splenomegaly in pregnancy in a malaria endemic area in Papua New Guinea. ( Alpers, MP; Brabin, BJ; Brabin, LR; Sapau, J, 1988) |
| "To determine the effects of chloroquine phosphate (300 mg base weekly) chemoprophylaxis for malaria provided by volunteer village health helpers (VHH's), pregnant women attending antenatal clinics in Saradidi, Kenya, were examined each month." | 3.67 | Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. II. Effect on parasitaemia and haemoglobin levels. ( Huong, AY; Kaseje, DC; Roberts, JM; Sempebwa, EK; Spencer, HC, 1987) |
| "Parasitaemia and antimalarial antibodies were examined from May 1983 to March 1984 in monthly samples taken from 930 pregnant women attending antenatal clinics in Saradidi, Kenya, and 317 of their infants; 104 women were taking chloroquine phosphate 300 mg base weekly for chemoprophylaxis." | 3.67 | Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. III. Serologic studies. ( Collins, WE; Huong, AY; Kaseje, DC; Roberts, JM; Shehata, MG; Spencer, HC; Stanfill, PS; Turner, A, 1987) |
| "Chemoprophylaxis using chloroquine (CQ) in suppressive doses has been recommended to protect pregnant women in malarious areas from the adverse effects of malaria during pregnancy." | 3.67 | In vivo response of Plasmodium falciparum to chloroquine in pregnant and non-pregnant women in Siaya District, Kenya. ( Brandling-Bennett, AD; Churchill, FC; Kaseje, DC; Schwartz, IK; Steketee, RW, 1987) |
| "Chloroquine prophylaxis for malaria was available free of charge to pregnant women in Saradidi, Kenya." | 3.67 | Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. I. Reasons for non-acceptance. ( Kaseje, DC; Sempebwa, EK; Spencer, HC, 1987) |
| "A cohort of 169 births to women who were exposed throughout pregnancy to chloroquine 300 mg base once a week for chemosuppression of malaria was studied." | 3.67 | Safety of chloroquine in chemosuppression of malaria during pregnancy. ( Cordero, JF; Wolfe, MS, 1985) |
| "Malaria in pregnancy is one of the most common preventable causes of maternal and neonatal morbidity and mortality in sub-Saharan Africa." | 2.78 | Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa. ( Chandra, RS; Duparc, S; Orazem, J; Robbins, J; Ubben, D; Vandenbroucke, P, 2013) |
| "Malaria is frequently a deadly disease, particularly in tropical countries of the world where this protozoan infection is endemic." | 2.41 | Malaria: a rising incidence in the United States. ( Broder, JS; Colletti, JE; Geroff, AJ; Grundmann, KA; Hanna, JR; Jerrard, DA; Mattu, A, 2002) |
| " A dosage of chloroquine base (25 mg/kg of body weight) was given to women over a 3-day period, followed by 5 mg/kg doses administered weekly for 4 weeks." | 1.28 | Malaria and pregnancy in Cameroonian women. Effect of pregnancy on Plasmodium falciparum parasitemia and the response to chloroquine. ( Campbell, CC; James, MA; Mvondo, JL, 1992) |
| " Reappraisal of quinine therapy has led to important modifications in dosage recommendations and recognition of a major complication of severe malaria associated with its use--hypoglycaemia." | 1.27 | Management of Plasmodium falciparum malaria. ( Phillips, RE, 1984) |
| "Chloroquine resistance was confirmed by testing in vitro and in vivo." | 1.27 | Multiple drug resistant Plasmodium falciparum malaria in a pregnant indigenous Zambian woman. ( Rolfe, M, 1988) |
| "Malaria is a potentially lethal disease." | 1.27 | Malaria in pregnancy. ( Moodley, J; Moodley, SC; Richards, A; Sankar, D, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (47.83) | 18.7374 |
| 1990's | 18 (19.57) | 18.2507 |
| 2000's | 17 (18.48) | 29.6817 |
| 2010's | 9 (9.78) | 24.3611 |
| 2020's | 4 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Olaleye, OA | 1 |
| Zash, R | 1 |
| Diseko, M | 1 |
| Mayondi, G | 1 |
| Mabuta, J | 1 |
| Lockman, S | 1 |
| Melton, ML | 1 |
| Mmalane, M | 1 |
| Makhema, J | 1 |
| Shapiro, RL | 1 |
| Zhao, X | 1 |
| Jiang, Y | 1 |
| Zhao, Y | 1 |
| Xi, H | 1 |
| Liu, C | 1 |
| Qu, F | 1 |
| Feng, X | 1 |
| Castro-Cavadía, CJ | 1 |
| Carmona-Fonseca, J | 1 |
| Axfors, C | 1 |
| Schmitt, AM | 1 |
| Janiaud, P | 1 |
| Van't Hooft, J | 1 |
| Abd-Elsalam, S | 1 |
| Abdo, EF | 1 |
| Abella, BS | 1 |
| Akram, J | 1 |
| Amaravadi, RK | 1 |
| Angus, DC | 1 |
| Arabi, YM | 1 |
| Azhar, S | 1 |
| Baden, LR | 1 |
| Baker, AW | 1 |
| Belkhir, L | 1 |
| Benfield, T | 1 |
| Berrevoets, MAH | 1 |
| Chen, CP | 1 |
| Chen, TC | 1 |
| Cheng, SH | 1 |
| Cheng, CY | 1 |
| Chung, WS | 1 |
| Cohen, YZ | 1 |
| Cowan, LN | 1 |
| Dalgard, O | 1 |
| de Almeida E Val, FF | 1 |
| de Lacerda, MVG | 1 |
| de Melo, GC | 1 |
| Derde, L | 1 |
| Dubee, V | 1 |
| Elfakir, A | 1 |
| Gordon, AC | 1 |
| Hernandez-Cardenas, CM | 1 |
| Hills, T | 1 |
| Hoepelman, AIM | 1 |
| Huang, YW | 1 |
| Igau, B | 1 |
| Jin, R | 1 |
| Jurado-Camacho, F | 1 |
| Khan, KS | 1 |
| Kremsner, PG | 1 |
| Kreuels, B | 1 |
| Kuo, CY | 1 |
| Le, T | 1 |
| Lin, YC | 1 |
| Lin, WP | 1 |
| Lin, TH | 1 |
| Lyngbakken, MN | 1 |
| McArthur, C | 1 |
| McVerry, BJ | 1 |
| Meza-Meneses, P | 1 |
| Monteiro, WM | 1 |
| Morpeth, SC | 1 |
| Mourad, A | 1 |
| Mulligan, MJ | 1 |
| Murthy, S | 1 |
| Naggie, S | 1 |
| Narayanasamy, S | 1 |
| Nichol, A | 1 |
| Novack, LA | 1 |
| O'Brien, SM | 1 |
| Okeke, NL | 1 |
| Perez, L | 1 |
| Perez-Padilla, R | 1 |
| Perrin, L | 1 |
| Remigio-Luna, A | 1 |
| Rivera-Martinez, NE | 1 |
| Rockhold, FW | 1 |
| Rodriguez-Llamazares, S | 1 |
| Rolfe, R | 1 |
| Rosa, R | 1 |
| Røsjø, H | 1 |
| Sampaio, VS | 1 |
| Seto, TB | 1 |
| Shahzad, M | 1 |
| Soliman, S | 1 |
| Stout, JE | 1 |
| Thirion-Romero, I | 1 |
| Troxel, AB | 1 |
| Tseng, TY | 1 |
| Turner, NA | 1 |
| Ulrich, RJ | 1 |
| Walsh, SR | 1 |
| Webb, SA | 1 |
| Weehuizen, JM | 1 |
| Velinova, M | 1 |
| Wong, HL | 1 |
| Wrenn, R | 1 |
| Zampieri, FG | 1 |
| Zhong, W | 1 |
| Moher, D | 1 |
| Goodman, SN | 1 |
| Ioannidis, JPA | 1 |
| Hemkens, LG | 1 |
| Frauchiger, B | 1 |
| Koch, D | 1 |
| Gaehler, A | 1 |
| Blum, J | 1 |
| Lurà, M | 1 |
| Kaiser, D | 1 |
| Buettcher, M | 1 |
| Chandra, RS | 1 |
| Orazem, J | 1 |
| Ubben, D | 1 |
| Duparc, S | 1 |
| Robbins, J | 1 |
| Vandenbroucke, P | 1 |
| White, NJ | 4 |
| Pukrittayakamee, S | 1 |
| Hien, TT | 1 |
| Faiz, MA | 1 |
| Mokuolu, OA | 1 |
| Dondorp, AM | 1 |
| Andrew, EV | 1 |
| Pell, C | 1 |
| Angwin, A | 1 |
| Auwun, A | 1 |
| Daniels, J | 1 |
| Mueller, I | 1 |
| Phuanukoonnon, S | 1 |
| Pool, R | 1 |
| Gies, S | 1 |
| Coulibaly, SO | 1 |
| Ouattara, FT | 1 |
| Ky, C | 1 |
| Brabin, BJ | 5 |
| D'Alessandro, U | 1 |
| Tiono, AB | 2 |
| Ouedraogo, A | 2 |
| Bougouma, EC | 2 |
| Diarra, A | 2 |
| Konaté, AT | 2 |
| Nébié, I | 2 |
| Sirima, SB | 2 |
| Oster, N | 1 |
| Rohrbach, P | 1 |
| Sanchez, CP | 1 |
| Andrews, KT | 1 |
| Kammer, J | 1 |
| Coulibaly, B | 1 |
| Stieglbauer, G | 1 |
| Becher, H | 1 |
| Lanzer, M | 1 |
| Chico, RM | 2 |
| Chandramohan, D | 2 |
| Rijken, MJ | 1 |
| Boel, ME | 1 |
| Russell, B | 1 |
| Imwong, M | 1 |
| Leimanis, ML | 1 |
| Phyo, AP | 1 |
| Muehlenbachs, A | 1 |
| Lindegardh, N | 1 |
| McGready, R | 2 |
| Rénia, L | 1 |
| Snounou, G | 1 |
| Singhasivanon, P | 1 |
| Nosten, F | 2 |
| Randriambelomanana, JA | 1 |
| Rakotoarisoa, H | 1 |
| Herinirina, SA | 1 |
| Zafindravola, BA | 1 |
| Andrianampanalinarivo, HR | 1 |
| Jerrard, DA | 1 |
| Broder, JS | 1 |
| Hanna, JR | 1 |
| Colletti, JE | 1 |
| Grundmann, KA | 1 |
| Geroff, AJ | 1 |
| Mattu, A | 1 |
| Carré, N | 1 |
| Eono, P | 1 |
| Kouakou, K | 1 |
| Duponchel, JL | 1 |
| Marquis, M | 1 |
| Zahui, KH | 1 |
| Neely, M | 1 |
| Kalyesubula, I | 1 |
| Bagenda, D | 1 |
| Myers, C | 1 |
| Olness, K | 1 |
| Olayemi, O | 1 |
| Fehintola, FA | 1 |
| Osungbade, A | 1 |
| Aimakhu, CO | 1 |
| Udoh, ES | 1 |
| Adeniji, AR | 1 |
| MORLEY, D | 1 |
| WOODLAND, M | 1 |
| CUTHBERTSON, WF | 1 |
| LOUIS, CJ | 1 |
| STONE, CT | 1 |
| Adam, I | 1 |
| Elbashir, MI | 1 |
| Bertin, G | 1 |
| Ndam, NT | 1 |
| Jafari-Guemouri, S | 1 |
| Fievet, N | 2 |
| Renart, E | 1 |
| Sow, S | 1 |
| Le Hesran, JY | 1 |
| Deloron, P | 1 |
| Randrianarivelojosia, M | 1 |
| Fidock, DA | 1 |
| Belmonte, O | 1 |
| Valderramos, SG | 1 |
| Mercereau-Puijalon, O | 1 |
| Ariey, F | 1 |
| Kalanda, GC | 1 |
| Hill, J | 1 |
| Verhoeff, FH | 1 |
| Villegas, L | 1 |
| Htway, M | 1 |
| Paw, MK | 1 |
| Pimanpanarak, M | 1 |
| Arunjerdja, R | 1 |
| Viladpai-Nguen, SJ | 1 |
| Greenwood, B | 1 |
| Denoeud, L | 1 |
| Aubouy, A | 1 |
| Ayemonna, P | 1 |
| Kiniffo, R | 1 |
| Massougbodji, A | 1 |
| Cot, M | 2 |
| Mayxay, M | 1 |
| Pongvongsa, T | 1 |
| Phompida, S | 1 |
| Phetsouvanh, R | 1 |
| Newton, PN | 1 |
| Nyunt, MM | 1 |
| Plowe, CV | 1 |
| Wiltz, SA | 1 |
| Crawford, P | 1 |
| Nichols, W | 1 |
| Hayes, M | 1 |
| Diallo, M | 1 |
| Dabo, CA | 1 |
| Saye, R | 1 |
| Yattara, O | 1 |
| Diarra, MA | 1 |
| Kayentao, K | 1 |
| Ongoiba, A | 1 |
| Sangho, H | 1 |
| Doumbo, O | 1 |
| Wyler, DJ | 1 |
| Main, EK | 1 |
| Main, DM | 1 |
| Krogstad, DJ | 1 |
| Warrell, DA | 1 |
| Pappas, C | 1 |
| Spracklen, FH | 2 |
| Phillips, RE | 1 |
| Flici, O | 1 |
| Tadjerouni, A | 1 |
| Leroy, F | 1 |
| Teys, JP | 1 |
| Hubinont, PO | 1 |
| Sharp, PT | 1 |
| Harvey, P | 1 |
| Feberwee, JD | 1 |
| Gilles, HM | 1 |
| Karol, MD | 1 |
| Conner, CS | 1 |
| Watanabe, AS | 1 |
| Murphrey, KJ | 1 |
| Ibeziako, PA | 1 |
| Williams, AI | 1 |
| Steketee, RW | 3 |
| Wirima, JJ | 2 |
| Bloland, PB | 1 |
| Chilima, B | 1 |
| Mermin, JH | 1 |
| Chitsulo, L | 1 |
| Breman, JG | 2 |
| Wenzel-Simon, A | 1 |
| Bienzle, U | 1 |
| Bauer, K | 1 |
| Dietrich, M | 1 |
| Moody, P | 1 |
| Wagner, VP | 1 |
| Smale, LE | 1 |
| Lischke, JH | 1 |
| Feigl, A | 1 |
| Feigl, D | 1 |
| Shem-Tov, A | 1 |
| Brish, M | 1 |
| Rotem, J | 1 |
| Berthoud, F | 1 |
| Rukaria, RM | 1 |
| Ojwang, SB | 1 |
| Oyieke, JB | 1 |
| Kigondu, CB | 1 |
| Cook, GC | 1 |
| Roisin, A | 1 |
| Barro, D | 1 |
| Yada, A | 1 |
| Verhave, JP | 1 |
| Carnevale, P | 1 |
| Breart, G | 1 |
| Nathwani, D | 1 |
| Currie, PF | 1 |
| Douglas, JG | 1 |
| Green, ST | 1 |
| Smith, NC | 1 |
| Davies, HD | 1 |
| Keystone, J | 1 |
| Lester, ML | 1 |
| Gold, R | 1 |
| Mvondo, JL | 1 |
| James, MA | 1 |
| Campbell, CC | 2 |
| Hennequin, C | 1 |
| Bourée, P | 1 |
| Pène, P | 1 |
| Delmont, J | 1 |
| Fleming, AF | 1 |
| Levy, M | 1 |
| Buskila, D | 1 |
| Gladman, DD | 1 |
| Urowitz, MB | 1 |
| Koren, G | 1 |
| Ginny, M | 1 |
| Alpers, M | 1 |
| Brabin, L | 1 |
| Eggelte, T | 2 |
| Van der Kaay, HJ | 2 |
| Joffe, A | 1 |
| Jadavji, T | 1 |
| Keuter, M | 1 |
| van Eijk, A | 1 |
| Hoogstrate, M | 1 |
| Raasveld, M | 1 |
| van de Ree, M | 1 |
| Ngwawe, WA | 1 |
| Watkins, WM | 1 |
| Were, JB | 1 |
| Brandling-Bennett, AD | 2 |
| Pathak, G | 1 |
| Asnani, PJ | 1 |
| Vinayak, VK | 1 |
| Endeshaw, Y | 1 |
| Assefa, D | 1 |
| Vogt, M | 1 |
| Burghard, R | 1 |
| Rüschoff, J | 1 |
| Nahlen, BL | 1 |
| Akintunde, A | 1 |
| Alakija, T | 1 |
| Nguyen-Dinh, P | 1 |
| Ogunbode, O | 1 |
| Edungbola, LD | 1 |
| Adetoro, O | 1 |
| Piccione, E | 1 |
| Klever, HJ | 1 |
| Witte, AM | 1 |
| Alpers, MP | 2 |
| McDermott, JM | 1 |
| Heymann, DL | 1 |
| Macheso, AP | 1 |
| Wahl, RD | 1 |
| Rolfe, M | 1 |
| Brabin, LR | 1 |
| Sapau, J | 1 |
| Mola, GL | 1 |
| Wanganapi, A | 1 |
| Spencer, HC | 3 |
| Kaseje, DC | 4 |
| Sempebwa, EK | 2 |
| Huong, AY | 2 |
| Roberts, JM | 2 |
| Collins, WE | 1 |
| Shehata, MG | 1 |
| Turner, A | 1 |
| Stanfill, PS | 1 |
| Kothare, SV | 1 |
| Kallapur, SG | 1 |
| Irani, SF | 1 |
| Prabhu, SB | 1 |
| Gangal, PS | 1 |
| Agarwal, GJ | 1 |
| Schwartz, IK | 1 |
| Churchill, FC | 1 |
| Monteagudo, FS | 1 |
| Sankar, D | 1 |
| Richards, A | 1 |
| Moodley, J | 1 |
| Moodley, SC | 1 |
| van Zon, AA | 1 |
| Eling, WM | 1 |
| Hermsen, CC | 1 |
| Panton, LJ | 1 |
| Tulloch, S | 1 |
| Bradley, AK | 1 |
| Greenwood, BM | 1 |
| Wolfe, MS | 1 |
| Cordero, JF | 1 |
| Stillman, AE | 1 |
| Alvarez, V | 1 |
| Grube, D | 1 |
| Lewis, R | 1 |
| Lauersen, NH | 1 |
| Birnbaum, S | 1 |
| Mitchell, AD | 1 |
| Hamilton, PJ | 1 |
| Gebbie, DA | 1 |
| Wilks, NE | 1 |
| Lothe, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care[NCT01976325] | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections[NCT05086887] | 715 participants (Anticipated) | Observational [Patient Registry] | 2019-04-15 | Recruiting | |||
| Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes[NCT02325180] | Phase 4 | 338 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation[NCT00819390] | Phase 2 | 70 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment[NCT00126971] | Phase 1 | 132 participants | Interventional | 2005-07-31 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -2.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | -0.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -3.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -1.2 |
The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Pre-entry, entry, Weeks 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 10.8 |
| C: Chloroquine Then Placebo for On-ART Participants | -2.4 |
For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -2.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -3.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -2.9 |
The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+ (NCT00819390)
Timeframe: At Weeks 10, 12, 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 5.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -0.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -2.9 |
Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12
| Intervention | cells/mm^3 (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -27 |
| B: Placebo Then Chloroquine for Off-ART Participants | -11 |
| C: Chloroquine Then Placebo for On-ART Participants | -6 |
| D: Placebo Then Chloroquine for On-ART Participants | 7 |
Results reported are for entry fasting LPS. (NCT00819390)
Timeframe: At entry
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 13.68 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.64 |
| C: Chloroquine Then Placebo for On-ART Participants | 8.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 7.00 |
Results reported are the week 12 fasting LPS. (NCT00819390)
Timeframe: At week 12
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 14.37 |
| B: Placebo Then Chloroquine for Off-ART Participants | 13.06 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 7.00 |
Results reported are the week 24 fasting LPS. (NCT00819390)
Timeframe: At week 24
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 20.54 |
| B: Placebo Then Chloroquine for Off-ART Participants | 2.83 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 8.00 |
Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants. (NCT00819390)
Timeframe: At Entry
| Intervention | log10 copies/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 4.48 |
| B: Placebo Then Chloroquine for Off-ART Participants | 4.42 |
Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment. (NCT00819390)
Timeframe: From start of study treatment to study completion at week 28
| Intervention | participants (Number) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1 |
| C: Chloroquine Then Placebo for On-ART Participants | 1 |
| D: Placebo Then Chloroquine for On-ART Participants | 0 |
Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 8.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 9.8 |
| C: Chloroquine Then Placebo for On-ART Participants | 8.7 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.9 |
Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 12
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 6.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 10.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.7 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.0 |
Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 24
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 11.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 12.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.3 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.2 |
Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 71.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 77.0 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.8 |
| D: Placebo Then Chloroquine for On-ART Participants | 49.9 |
Results reported are the week 12 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 12
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 71.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 79.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.9 |
| D: Placebo Then Chloroquine for On-ART Participants | 51.9 |
Results reported are the week 24 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 24
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 78.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 79.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.6 |
| D: Placebo Then Chloroquine for On-ART Participants | 48.7 |
Baseline sCD14 was computed as the mean of pre-entry and entry sCD14. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.43 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.97 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.80 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.58 |
Results reported are the week 12 sCD14. (NCT00819390)
Timeframe: At week 12
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.88 |
| C: Chloroquine Then Placebo for On-ART Participants | 2.04 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.63 |
Results reported are the week 24 sCD14. (NCT00819390)
Timeframe: At week 24
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 2.19 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.77 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.72 |
Results reported are for HIV-1 RNA at study entry for on-ART participants. (NCT00819390)
Timeframe: At Entry
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 16 | 2 |
| D: Placebo Then Chloroquine for On-ART Participants | 17 | 2 |
Results reported are for HIV-1 RNA at week 12 for on-ART participants. (NCT00819390)
Timeframe: At week 12
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 16 | 1 |
| D: Placebo Then Chloroquine for On-ART Participants | 18 | 1 |
Results reported are for HIV-1 RNA at week 24 for on-ART participants. (NCT00819390)
Timeframe: At week 24
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 14 | 2 |
| D: Placebo Then Chloroquine for On-ART Participants | 18 | 1 |
Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants. (NCT00819390)
Timeframe: At weeks 12 and 24
| Intervention | log10 copies/mL (Median) | |
|---|---|---|
| Week 12 | Week 24 | |
| A: Chloroquine Then Placebo for Off-ART Participants | 4.68 | 4.69 |
| B: Placebo Then Chloroquine for Off-ART Participants | 4.28 | 4.61 |
Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.65 | 1228.66 | 286390 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.62 | 1377.81 | 328460 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.01 | 1316.63 | 107890 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.51 | 1250.85 | 103530 |
Results reported are the week 12 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 12
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.68 | 1209.50 | 251320 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.28 | 1347.06 | 319770 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.15 | 1441.35 | 126540 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.30 | 1304.77 | 117890 |
Results reported are the week 24 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 24
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.34 | 1327.21 | 264240 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.18 | 1420.30 | 294780 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.02 | 1230.21 | 100860 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.27 | 1176.20 | 124920 |
Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.03 | 45.48 | 9.12 | 2.52 | 1.04 | 38.60 | 96.29 | 9.82 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.03 | 36.15 | 9.35 | 6.13 | 0.83 | 39.94 | 97.52 | 16.37 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.13 | 19.91 | 10.96 | 4.48 | 1.31 | 48.17 | 96.11 | 4.58 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.07 | 23.65 | 12.66 | 6.49 | 1.17 | 26.08 | 95.38 | 8.28 |
Results reported are the week 12 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 12
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.00 | 51.90 | 7.66 | 3.74 | 0.84 | 43.51 | 97.90 | 15.03 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.05 | 40.49 | 8.48 | 8.43 | 1.03 | 36.47 | 97.18 | 16.32 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.10 | 14.70 | 13.93 | 7.24 | 1.47 | 47.83 | 95.40 | 7.10 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.14 | 18.20 | 13.64 | 5.16 | 1.01 | 26.75 | 95.15 | 6.09 |
Results reported are the week 24 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 24
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.05 | 44.50 | 10.13 | 4.34 | 0.94 | 41.21 | 97.70 | 9.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.00 | 38.96 | 7.89 | 7.45 | 1.12 | 33.19 | 97.05 | 14.84 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.08 | 14.80 | 11.79 | 5.63 | 0.76 | 36.65 | 96.69 | 4.13 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.16 | 17.65 | 12.88 | 6.52 | 1.39 | 24.14 | 92.41 | 7.49 |
12 reviews available for chloroquine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Me | 2020 |
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Topics: Adult; Child; Chloroquine; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Drug Treatment | 2021 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, Combination; F | 2011 |
Malaria: a rising incidence in the United States.
Topics: Antimalarials; Chemoprevention; Chloroquine; Drug Combinations; Drug Resistance; Female; Global Heal | 2002 |
Comparative efficacy of chloroquine and sulphadoxine--pyrimethamine in pregnant women and children: a meta-analysis.
Topics: Adolescent; Adult; Africa; Antimalarials; Child; Chloroquine; Drug Combinations; Endemic Diseases; F | 2006 |
Clinical inquiries. What is the most effective and safe malaria prophylaxis during pregnancy?
Topics: Abnormalities, Drug-Induced; Antimalarials; Chemoprevention; Chloroquine; Doxycycline; Female; Human | 2008 |
Malaria--resurgence, resistance, and research. (First of two parts).
Topics: Antimalarials; Chloroquine; DDT; Drug Resistance, Microbial; Europe; Female; Humans; Malaria; Mosqui | 1983 |
Malaria 1984. Part I. Malaria prophylaxis.
Topics: Antimalarials; Chloroquine; Dapsone; Drug Combinations; Drug Resistance, Microbial; Female; Humans; | 1984 |
[Malaria in pregnant women. Presentation of 2 cases and review of the literature].
Topics: Abortion, Spontaneous; Acute Kidney Injury; Adult; Anemia, Hemolytic; Antimalarials; Brain Diseases; | 1982 |
Plasmodium falciparum malaria in pregnancy: a review.
Topics: Animals; Chloroquine; Critical Care; Female; Humans; Immunocompromised Host; Malaria, Falciparum; Me | 1992 |
[The synthesis of the epidemiology and treatment of malaria of the pregnant woman and the infant in subsaharan Africa].
Topics: Africa; Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Infant; Infant, Newbor | 1991 |
13 trials available for chloroquine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa.
Topics: Africa; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Malaria; Pregna | 2013 |
A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso.
Topics: Adolescent; Adult; Antimalarials; Burkina Faso; Chloroquine; Drug Combinations; Female; Health Promo | 2008 |
Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens.
Topics: Adult; Animals; Antimalarials; Burkina Faso; Chemoprevention; Chloroquine; Drug Combinations; Female | 2009 |
Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Anemia; Antimalarials; Child Development; Chloroquine; Double-Blind Method; Femal | 2007 |
Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin.
Topics: Adult; Anemia; Antimalarials; Bedding and Linens; Benin; Birth Weight; Chloroquine; Drug Administrat | 2007 |
[Randomized clinical trial of two malaria prophylaxis regimens for pregnant women in Faladie, Mali].
Topics: Adult; Anemia; Antimalarials; Chloroquine; Drug Combinations; Endemic Diseases; Female; Humans; Infa | 2007 |
[Comparative impact of three malaria preventive regimens during pregnancy on maternal anemia due to malaria in Burkina Faso].
Topics: Adult; Anemia; Antimalarials; Burkina Faso; Chloroquine; Drug Therapy, Combination; Female; Humans; | 2008 |
Effect of chloroquine chemoprophylaxis during pregnancy on birth weight: results of a randomized trial.
Topics: Adult; Birth Weight; Burkina Faso; Chloroquine; Female; Humans; Malaria; Placenta Diseases; Pregnanc | 1992 |
Antimalarial prophylaxis in pregnant Nigerian women.
Topics: Animals; Chloroquine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Malaria; Niger | 1990 |
Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Dapsone; Drug Therapy, Combination; Female; | 1990 |
Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Evaluation; Drug Resistance; Female; Follow-Up Studies | 1989 |
Efficacy of chemoprophylaxis in preventing Plasmodium falciparum parasitaemia and placental infection in pregnant women in Malawi.
Topics: Amodiaquine; Animals; Chloroquine; Female; Humans; Malaria; Malawi; Placenta Diseases; Plasmodium fa | 1988 |
The role of malaria, folic acid deficiency and haemoglobin AS in pregnancy at Mulago hospital.
Topics: Adolescent; Adult; Anemia; Anemia, Hypochromic; Birth Weight; Blood Volume Determination; Chloroquin | 1972 |
67 other studies available for chloroquine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Impact of prophylactic antimalarials in pregnant women living with Human Immunodeficiency Virus on birth outcomes in Botswana.
Topics: Antimalarials; Botswana; Chloroquine; Female; HIV; HIV Infections; Humans; Infant, Newborn; Malaria; | 2022 |
ASSESSMENT OF THE EFFICACY AND SAFETY OF CHLOROQUINE MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED GESTATIONAL MALARIA CAUSED BY
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Chloroquine; Colombia; Drug Evaluation; Female; Fol | 2020 |
Don't forget the past: A sleeping disease can be awakened.
Topics: Chloroquine; Emergency Service, Hospital; Emigration and Immigration; Eritrea; Female; Fever; Humans | 2019 |
Knowledge, attitudes, and practices concerning malaria in pregnancy: results from a qualitative study in Madang, Papua New Guinea.
Topics: Adult; Antimalarials; Chloroquine; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Huma | 2015 |
Apparent bias for P. falciparum parasites carrying the wild-type pfcrt allele in the placenta.
Topics: Adolescent; Adult; Animals; Blood; Chloroquine; Drug Resistance; Female; Gene Frequency; Humans; Mal | 2010 |
Quinine for the treatment of malaria in pregnancy.
Topics: Animals; Antimalarials; Azithromycin; Chloroquine; Clindamycin; Drug Therapy, Combination; Female; H | 2010 |
Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand.
Topics: Adult; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Female; Genotype; Humans; Malari | 2011 |
[Comparison of efficacy of chloroquine versus sulfadoxine-pyrimethamine in malaria prevention in pregnant women in the Toamasina region (Madagascar)].
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Combinations; Endemic Diseases; Female; Humans; | 2011 |
[Iron supplementation associated with malaria prevention among pregnant women in Abidjan].
Topics: Adult; Analysis of Variance; Anemia, Iron-Deficiency; Antimalarials; Attitude of Health Personnel; C | 2003 |
Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission.
Topics: Animals; Antimalarials; Chloroquine; Chromatography, High Pressure Liquid; Cohort Studies; Female; F | 2003 |
Pattern of chloroquine-induced pruritus in antenatal patients at the University College Hospital, Ibadan.
Topics: Adult; Antimalarials; Chloroquine; Cross-Sectional Studies; Female; Humans; Malaria; Pregnancy; Preg | 2003 |
CONTROLLED TRIAL OF PYRIMETHAMINE IN PREGNANT WOMEN IN AN AFRICAN VILLAGE.
Topics: Birth Weight; Chloroquine; Female; Humans; Infant; Infant Mortality; Lactose; Malaria; Nigeria; Preg | 1964 |
MALARIA OCCURRING DURING THE PUERPERIUM AND IN THE NEONATE.
Topics: Chloroquine; Drug Therapy; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Mal | 1965 |
SAFETY OF CHLOROQUINE IN PREGNANCY.
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Communicable Diseases; Drug Therapy; Female; Pregnanc | 1965 |
Acute gluteal abscess due to chloroquine injection in Sudanese pregnant woman.
Topics: Abscess; Adult; Antimalarials; Buttocks; Chloroquine; Drainage; Female; Humans; Injections, Intramus | 2004 |
High prevalence of Plasmodium falciparum pfcrt K76T mutation in pregnant women taking chloroquine prophylaxis in Senegal.
Topics: Adult; Animals; Antimalarials; Chemoprevention; Chloroquine; DNA, Protozoan; Drug Resistance; Female | 2005 |
First evidence of pfcrt mutant Plasmodium falciparum in Madagascar.
Topics: Animals; Antimalarials; Chloroquine; Codon; Drug Resistance; Female; Humans; Madagascar; Malaria, Fa | 2006 |
Diagnosis and management of malaria by rural community health providers in the Lao People's Democratic Republic (Laos).
Topics: Administration, Oral; Adult; Antimalarials; Child; Chloroquine; Clinical Competence; Community Healt | 2007 |
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Design; | 2007 |
Treatment of chloroquine-resistant malaria during pregnancy.
Topics: Adult; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria; Plasmodium falciparum; Pregn | 1983 |
Clinical management of chloroquine-resistant Plasmodium falciparum malaria in Southeast Asia.
Topics: Antimalarials; Asia, Southeastern; Chloroquine; Drug Resistance, Microbial; Female; Humans; Malaria; | 1983 |
Congenital Plasmodium vivax malaria.
Topics: Adult; Chloroquine; Female; Humans; Infant, Newborn; Malaria; Plasmodium vivax; Pregnancy; Pregnancy | 1984 |
Management of Plasmodium falciparum malaria.
Topics: Amodiaquine; Anemia; Antimalarials; Brain Diseases; Chloroquine; Drug Resistance; Female; Humans; Hy | 1984 |
Malaria prevention in travellers from the United Kingdom. Report of meetings convened by the Ross Institute.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedule; Drug | 1981 |
Malaria and growth stunting in young children of the highlands of Papua New Guinea.
Topics: Amodiaquine; Anthropometry; Child; Child, Preschool; Chloroquine; Female; Growth Disorders; Health S | 1980 |
A pyrimethamine-chloroquine combination for malaria prophylaxis during pregnancy.
Topics: Abnormalities, Drug-Induced; Chloroquine; Drug Combinations; Female; Fetus; Humans; Malaria; Pregnan | 1982 |
The management and treatment of malaria (a personal view).
Topics: Chloroquine; Female; Humans; Malaria; Male; Pregnancy; Pregnancy Complications, Infectious; Proguani | 1980 |
Podophyllum: suspected teratogenicity from topical application.
Topics: Abnormalities, Drug-Induced; Administration, Topical; Adult; Chloroquine; Condylomata Acuminata; Fem | 1980 |
The effect of malarial chemoprophylaxis on immunoglobulin levels of pregnant Nigerian women and the newborn.
Topics: Chloroquine; Female; Fetal Blood; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immu | 1980 |
Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Delivery, Obstetric; Female; Fetal Blood; HIV Infecti | 1996 |
[Connatal malaria (author's transl)].
Topics: Adult; Chloroquine; Female; Humans; Infant; Malaria; Maternal-Fetal Exchange; Plasmodium vivax; Preg | 1977 |
Falciparum malaria despite chemoprophylaxis.
Topics: Chloroquine; Female; Fetal Diseases; Humans; Malaria; Plasmodium falciparum; Pregnancy; Pregnancy Co | 1979 |
Amebic abscess of the liver and spleen in pregnancy and the puerperium.
Topics: Adolescent; Adult; Amebiasis; Chloroquine; Emetine; Female; Humans; Infant, Newborn; Liver Abscess, | 1975 |
Congenital atrial flutter.
Topics: Atrial Flutter; Chloramphenicol; Chloroquine; Digoxin; Electrocardiography; Female; Fetal Diseases; | 1975 |
Letter: Malarial prophylaxis for pregnant women.
Topics: Chloroquine; Female; Fetus; Humans; Malaria; Pregnancy; Pregnancy Complications, Infectious | 1976 |
In vivo and in vitro response of Plasmodium falciparum to chloroquine in pregnant women in Kilifi district, Kenya.
Topics: Adult; Animals; Chloroquine; Drug Resistance; Female; Hospitals, District; Humans; Kenya; Malaria, F | 1992 |
Use of antiprotozoan and anthelmintic drugs during pregnancy: side-effects and contra-indications.
Topics: Abnormalities, Drug-Induced; Anthelmintics; Antimalarials; Antiprotozoal Agents; Chloroquine; Contra | 1992 |
Congenital malaria in infants of asymptomatic women.
Topics: Animals; Canada; Chloroquine; Female; Humans; India; Infant, Newborn; Malaria, Vivax; Male; Plasmodi | 1992 |
Malaria and pregnancy in Cameroonian women. Effect of pregnancy on Plasmodium falciparum parasitemia and the response to chloroquine.
Topics: Cameroon; Chloroquine; Cross-Sectional Studies; Female; Humans; Longitudinal Studies; Malaria, Falci | 1992 |
[Malaria of the pregnant woman and the newborn].
Topics: Adult; Animals; Cesarean Section; Chloroquine; Female; Fetal Diseases; Humans; Infant, Newborn; Mala | 1991 |
Pregnancy outcome following first trimester exposure to chloroquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Arthritis, Rheumatoid; Chloro | 1991 |
Recommendations for the prevention of malaria among travelers.
Topics: Adult; Animals; Antimalarials; Breast Feeding; Centers for Disease Control and Prevention, U.S.; Chi | 1990 |
Failure of chloroquine prophylaxis for falciparum malaria in pregnant women in Madang, Papua New Guinea.
Topics: Animals; Chloroquine; Enzyme-Linked Immunosorbent Assay; Female; Malaria; Papua New Guinea; Parity; | 1990 |
Congenital malaria: a case report of a preventable disease.
Topics: Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Infant, Newborn; Malaria; Male; Plasmodi | 1990 |
Effect of prior eradication of Plasmodium berghei infection on the foetal development and parasitaemic levels under the stress of pregnancy.
Topics: Animals; Body Weight; Chloroquine; Embryonic and Fetal Development; Female; Malaria; Mice; Plasmodiu | 1990 |
Cerebral malaria. Factors affecting outcome of treatment in a suboptimal clinical setting.
Topics: Adult; Brain Diseases; Chloroquine; Ethiopia; Female; Humans; Malaria; Male; Pregnancy; Pregnancy Co | 1990 |
[Congenital malaria--a rare neonatal infection].
Topics: Animals; Cesarean Section; Chloroquine; Diseases in Twins; Female; Humans; Infant, Newborn; Malaria; | 1990 |
[Problems of antiparasitic therapy in pregnancy].
Topics: Antiprotozoal Agents; Chloroquine; Female; Humans; Metronidazole; Parasitic Diseases; Pregnancy; Pre | 1988 |
In-vivo susceptibility of Plasmodium falciparum to cholorquine in pregnant and non-pregnant women and in-vitro response of P. falciparum to chloroquine and mefloquine in Madang Province, Papua New Guinea.
Topics: Animals; Antimalarials; Chloroquine; Female; Humans; In Vitro Techniques; Malaria; Mefloquine; Papua | 1988 |
Multiple drug resistant Plasmodium falciparum malaria in a pregnant indigenous Zambian woman.
Topics: Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Erythro | 1988 |
Recommendations for the prevention of malaria in travelers.
Topics: Antimalarials; Breast Feeding; Child; Chloroquine; DEET; Drug Resistance; Female; Government Publica | 1988 |
A longitudinal study of splenomegaly in pregnancy in a malaria endemic area in Papua New Guinea.
Topics: Adolescent; Adult; Chloroquine; Female; Humans; Longitudinal Studies; Malaria; Papua New Guinea; Pre | 1988 |
Failure of chloroquine malaria prophylaxis in pregnancy.
Topics: Chloroquine; Drug Resistance, Microbial; Female; Humans; Malaria; Papua New Guinea; Parity; Plasmodi | 1987 |
Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. II. Effect on parasitaemia and haemoglobin levels.
Topics: Adolescent; Adult; Animals; Chloroquine; Community Health Services; Female; Hemoglobins; Humans; Ken | 1987 |
Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. III. Serologic studies.
Topics: Animals; Antibodies; Antibody Formation; Chloroquine; Community Health Services; Enzyme-Linked Immun | 1987 |
Congenital malaria (a report of 2 cases).
Topics: Adult; Animals; Chloroquine; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Malaria; Mal | 1987 |
In vivo response of Plasmodium falciparum to chloroquine in pregnant and non-pregnant women in Siaya District, Kenya.
Topics: Animals; Chloroquine; Female; Humans; Kenya; Malaria; Parity; Plasmodium falciparum; Pregnancy; Preg | 1987 |
Leads from the MMWR. Recommendations for the prevention of malaria in travelers.
Topics: Antimalarials; Breast Feeding; Child; Chloroquine; DEET; Drug Resistance; Female; Government Publica | 1988 |
Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. I. Reasons for non-acceptance.
Topics: Adolescent; Adult; Attitude to Health; Chloroquine; Community Health Services; Fear; Female; Humans; | 1987 |
Malaria prophylaxis.
Topics: Antimalarials; Child; Chloroquine; Dapsone; Drug Combinations; Female; Humans; Malaria; Pregnancy; P | 1986 |
Malaria in pregnancy.
Topics: Adult; Chloroquine; Female; Humans; Malaria; Plasmodium falciparum; Pregnancy; Pregnancy Complicatio | 1985 |
Pregnancy-induced recrudescences strengthen malarial immunity in mice infected with Plasmodium berghei.
Topics: Adrenal Cortex Hormones; Animals; Antilymphocyte Serum; Chloroquine; Female; Immune Tolerance; Immun | 1985 |
Susceptibility of Plasmodium falciparum in The Gambia to pyrimethamine, Maloprim and chloroquine.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Dapsone; Dose-Response Relationship, Drug; Drug | 1985 |
Safety of chloroquine in chemosuppression of malaria during pregnancy.
Topics: Abnormalities, Drug-Induced; Chloroquine; Female; Humans; Infant, Newborn; Malaria; Male; Pregnancy; | 1985 |
Hepatic amebic abscess. Unresponsiveness to combination of metronidazole and surgical drainage.
Topics: Administration, Oral; Adult; Chloroquine; Drainage; Emetine; Female; Humans; Injections, Intramuscul | 1974 |
Malaria associated with pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Chloroquine; Female; Humans; Malaria; Plasmodium falciparum; Pre | 1973 |
Recent experiences with severe and cerebral malaria.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Brain Diseases; Child; Child, Preschool; Chloroquine; Co | 1974 |